Quinazolinone and pyridopyrimidine a-II antagonists
    3.
    发明授权
    Quinazolinone and pyridopyrimidine a-II antagonists 失效
    喹唑啉酮和吡啶并嘧啶a-II拮抗剂

    公开(公告)号:US5202322A

    公开(公告)日:1993-04-13

    申请号:US765626

    申请日:1991-09-25

    IPC分类号: C07D239/91 C07D239/96

    CPC分类号: C07D239/91 C07D239/96

    摘要: Substituted quinazolinones and pyridopyrimidines of structural formula 1 ##STR1## are angiotensin II antagonists useful in the treatment of disorders related to the reninangiotensin system (RAS) such as hypertension, congestive heart failure, ocular hypertension and certain CNS disorders.

    摘要翻译: 结构式1的取代喹唑啉酮和吡啶并嘧啶是可用于治疗与肾素血管紧张素系统(RAS)相关的疾病的血管紧张素II拮抗剂,例如高血压,充血性心力衰竭,高眼压症和某些中枢神经系统疾病。

    Substituted lactams as inhibitors of Aβ protein production
    6.
    发明授权
    Substituted lactams as inhibitors of Aβ protein production 有权
    取代的内酰胺作为Abeta蛋白质生产的抑制剂

    公开(公告)号:US07655647B2

    公开(公告)日:2010-02-02

    申请号:US12388944

    申请日:2009-02-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    Substituted lactams as inhibitors of abeta protein production
    9.
    发明申请
    Substituted lactams as inhibitors of abeta protein production 失效
    取代的内酰胺作为abeta蛋白质生产的抑制剂

    公开(公告)号:US20080221087A1

    公开(公告)日:2008-09-11

    申请号:US11788708

    申请日:2007-04-19

    摘要: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及式(I)的新型内酰胺:具有药物和生物影响性质,其药物组合物和使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。

    SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION
    10.
    发明申请
    SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION 失效
    作为ABETA蛋白生产抑制剂的苯甲酰胺

    公开(公告)号:US20080207602A1

    公开(公告)日:2008-08-28

    申请号:US12061227

    申请日:2008-04-02

    申请人: Richard E. Olson

    发明人: Richard E. Olson

    摘要: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

    摘要翻译: 本发明涉及具有式(I)的新型内酰胺:其药物组合物及其使用方法。 这些新化合物抑制淀粉样蛋白前体蛋白的加工,更具体地,抑制Aβ肽的产生,从而起到防止淀粉样蛋白质神经沉积的形成的作用。 更具体地,本发明涉及治疗与β-淀粉样蛋白产生相关的神经系统疾病,例如阿尔茨海默病和唐氏综合征。